VivoSeq
Dermatology

Actinic Keratoses

2

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Actinic Keratoses is an early-stage landscape with 2 programs across 6 companies. The most active players are DUSA Pharmaceuticals, Inc., MEDA Pharma GmbH & Co. KG, Graceway Pharmaceuticals, LLC. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

DUSA Pharmaceuticals, Inc.

1 program

PreclinicalM

MEDA Pharma GmbH & Co. KG

0 programs

PreclinicalG

Graceway Pharmaceuticals, LLC

0 programs

PreclinicalLEO Pharma logo

LEO Pharma

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalB

Biofrontera Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Chemical Peels

Northwestern University

Phase 3
No programs
Approved1

5fluorouracil

University of California, Davis

Analysis

Trial Status

48

clinical trials

Completed36 · 75%
Not yet recruiting3 · 6%
Unknown status3 · 6%
Terminated3 · 6%
Withdrawn2 · 4%
Enrolling by invitation1 · 2%

Clinical Trials

Trial Activity

48 trials

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
Not yet recruiting·WWest Virginia University·Phase 1·NCT07401277·32 enrolled
Efficacy of Topical 5-Fluorouracil Vs Calcipotriol As Photodynamic Therapy Pre-treatment for Field Actinic Keratoses
Not yet recruiting·SSt Vincent's University Hospital, Ireland·N/A·NCT06685588·50 enrolled
PDT Versus the Combination of Jessner's Solution and 35% TCA for Treatment of Actinic Keratoses on Upper Extremities: A Randomized Controlled Split-arm Trial
Not yet recruiting·NNorthwestern University·Phase 2·NCT04429308·60 enrolled
Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Prospective, Randomized Controlled, Intra-Individual Trial
Enrolling by invitation·UUniversity of California, Davis·Approved·NCT06461442·73 enrolled
An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses
Completed·Sanofi logoSanofi·Phase 4·NCT00377273·250 enrolled
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Completed·PPeplin·Phase 2·NCT00107965·60 enrolled
Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
Completed·DDerm Research @ 888 Inc.·Phase 4·NCT00110682·60 enrolled
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Completed·—·Phase 2·NCT04140292·75 enrolled
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Completed·JJoint Authority for Päijät-Häme Social and Health Care·Phase 4·NCT02464709·72 enrolled
Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
Completed·GGalderma R&D·Phase 3·NCT01821391·131 enrolled
Treatment of Actinic Keratoses (AK) on the Face
Completed·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT02411851·20 enrolled
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Completed·GGraceway Pharmaceuticals, LLC·Phase 3·NCT00605176·479 enrolled
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Completed·—·Phase 2·NCT06027619·30 enrolled
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
Completed·MMEDA Pharma GmbH & Co. KG·Phase 4·NCT00777127·258 enrolled
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
Completed·DDUSA Pharmaceuticals, Inc.·Phase 2·NCT01458587·70 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)